Abstract
Background
The objective of this study was to determine the features of fragment length for circulating cell-free DNA (cfDNA) from plasma and serum samples.
Methods
Plasma and serum samples from different sources were randomly collected. Circulating cfDNA was extracted and purified by a precipitation-enriched and spin-column-based kit. The concentration of the purified DNA was immediately measured by a highly sensitive dsDNA quantitative assay, and then the fragment length was analyzed by capillary electrophoresis. The abundance of a specific fragment was estimated by the area under curve (AUC) for the fragment peak in the capillary electrophoresis.
Results
A total of 199 plasma and 117 serum samples were extracted and analyzed. The average yield of cfDNA from the serum samples (131.67 ng/mL) was significantly higher than that from the plasma samples (32.78 ng/mL, p < 0.001). The average abundance of the 20–400 bp fragments in plasma cfDNA (84.4%) was significantly higher than that of serum cfDNA (51.9%, p < 0.001). Fragment peaks in serum cfDNA always presented in regions around 190 bp, 430 bp, and 630 bp, but plasma cfDNA generally showed a sharp peak in the 165–190 bp region and a much lower peak in the 300<uni-2013;400 bp region. Large fragments in plasma cfDNA were longer than 1000 bp and peaked around the 3000<uni-2013;4000 bp region while the large fragments in serum cfDNA were always shorter and peaked around the 1000 bp region.
Conclusions
The fragment lengths of serum cfDNA and plasma cfDNA have very different features. Fragment size selection is suitable for plasma cfDNA but may not apply to serum cfDNA.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: National Key R&D Program of China No. 2016YFC1302803. Key Disciplines of Chinese Medicine (Integrated Traditional Chinese and Western Medicine) in Zhejiang Province during the Thirteenth Five-year Plan period grant 2017-XK-A40.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Conflict of interest statement: Authors’ conflict of interest disclosure: Dr. Huang and Zheng are shareholders of BQbiolab Company Limited in Hangzhou China. Research funding played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Harraway J. Non-invasive prenatal testing. Aust Fam Physician 2017;46:735–9.Search in Google Scholar
2. Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC. A Phase II trial of osimertinib in the second-line treatment of non-small cell lung cancer with the EGFR T790M mutation, detected from circulating tumor DNA: liquidlung-O-cohort 2. Cancer Res Treat 2019;51:777–87.10.4143/crt.2018.387Search in Google Scholar PubMed PubMed Central
3. Montagut C, Argiles G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, et al. Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: a phase 2 randomized clinical trial. JAMA Oncol 2018;4:e175245.10.1001/jamaoncol.2017.5245Search in Google Scholar PubMed PubMed Central
4. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 2016;164:57–68.10.1016/j.cell.2015.11.050Search in Google Scholar PubMed PubMed Central
5. Board RE, Williams VS, Knight L, Shaw J, Greystoke A, Ranson M, et al. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann N Y Acad Sci 2008;1137:98–107.10.1196/annals.1448.020Search in Google Scholar PubMed
6. Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 2003;49:1028–9.10.1373/49.6.1028Search in Google Scholar PubMed
7. Lee TH, Montalvo L, Chrebtow V, Busch MP. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 2001;41:276–82.10.1046/j.1537-2995.2001.41020276.xSearch in Google Scholar PubMed
8. Huang G, Krocker JD, Kirk JL, Merwat SN, Ju H, Soloway RD, et al. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma. Clin Chem Lab Med 2014;52:899–909.10.1515/cclm-2013-0885Search in Google Scholar PubMed PubMed Central
9. Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, et al. First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer. J Clin Oncol 2017;35:3391–400.10.1200/JCO.2017.73.3246Search in Google Scholar PubMed PubMed Central
10. Lo YM, Chan KC, Sun H, Chen EZ, Jiang P, Lun FM, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2010;2:61ra91.10.1126/scitranslmed.3001720Search in Google Scholar PubMed
11. Volckmar AL, Sultmann H, Riediger A, Fioretos T, Schirmacher P, Endris V, et al. A field guide for cancer diagnostics using cell-free DNA: from principles to practice and clinical applications. Genes Chromosomes Cancer 2018;57:123–39.10.1002/gcc.22517Search in Google Scholar PubMed
12. Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med 2018;10: pii:eaat4921.10.1126/scitranslmed.aat4921Search in Google Scholar PubMed PubMed Central
13. Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, et al. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. J Transl Med 2018;16:300.10.1186/s12967-018-1677-2Search in Google Scholar PubMed PubMed Central
14. Umetani N, Hiramatsu S, Hoon DS. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann N Y Acad Sci 2006;1075:299–307.10.1196/annals.1368.040Search in Google Scholar PubMed
15. Iqbal S, Vishnubhatla S, Raina V, Sharma S, Gogia A, Deo SS, et al. Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer. Springerplus 2015;4:265.10.1186/s40064-015-1071-ySearch in Google Scholar PubMed PubMed Central
16. Tang Z, Li L, Shen L, Shen X, Ju S, Cong H. Diagnostic value of serum concentration and integrity of circulating cell-free DNA in breast cancer: a comparative study with CEA and CA15-3. Lab Med 2018;49:323–8.10.1093/labmed/lmy019Search in Google Scholar PubMed
17. Wasenang W, Chaiyarit P, Proungvitaya S, Limpaiboon T. Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases. Clin Epigenetics 2019;11:39.10.1186/s13148-019-0634-0Search in Google Scholar PubMed PubMed Central
18. Dunaeva M, Derksen M, Pruijn GJ. LINE-1 Hypermethylation in serum cell-free DNA of relapsing remitting multiple sclerosis patients. Mol Neurobiol 2018;55:4681–8.10.1007/s12035-017-0679-zSearch in Google Scholar PubMed PubMed Central
19. Lee JS, Kim M, Seong MW, Kim HS, Lee YK, Kang HJ. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction. Clin Chem Lab Med 2020;58:527–32.10.1515/cclm-2019-0896Search in Google Scholar PubMed
20. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 2018;36:1631–41.10.1200/JCO.2017.76.8671Search in Google Scholar PubMed
©2020 Walter de Gruyter GmbH, Berlin/Boston
